IMUX (Immunic) Cyclically Adjusted PB Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMUX Immunic Inc IMUX
32 GF Score
Price $15.40
! 3 Warning Signs
View Full Analysis

What is Immunic Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunic  (NAS:IMUX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Immunic Cyclically Adjusted PB Ratio Related Terms


Immunic Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Immunic's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic Cyclically Adjusted PB Ratio Chart

Immunic Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.03 0.03 0.02 0.02

Immunic Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.02 0.05 0.00

IMUX vs MDWD, WHWK, IVVD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Immunic's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Immunic's Cyclically Adjusted PB Ratio falls into.


IMUX
32GF Score
Immunic Inc IMUX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunic Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Immunic's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Immunic's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.001/333.9520*333.9520
=3.001

Current CPI (Jun. 2026) = 333.9520.

Immunic Quarterly Data

Book Value per Share CPI Adj_Book
201609 847.000 241.428 1,171.601
201612 730.575 241.432 1,010.541
201703 796.491 243.801 1,091.012
201706 691.858 244.955 943.224
201709 585.642 246.819 792.388
201712 472.113 246.524 639.545
201803 351.840 249.554 470.831
201806 249.557 251.989 330.729
201809 134.453 252.439 177.868
201812 117.236 251.233 155.836
201903 85.368 254.202 112.150
201906 69.480 256.143 90.586
201909 60.106 256.759 78.176
201912 54.342 256.974 70.620
202003 46.662 258.115 60.372
202006 52.562 257.797 68.089
202009 78.608 260.280 100.858
202012 75.005 260.474 96.163
202103 63.194 264.877 79.674
202106 55.514 271.696 68.234
202109 55.415 274.310 67.464
202112 48.259 278.802 57.805
202203 47.182 287.504 54.805
202206 41.835 296.311 47.149
202209 35.605 296.808 40.061
202212 28.920 296.797 32.540
202303 20.545 301.836 22.731
202306 15.573 305.109 17.045
202309 10.854 307.789 11.777
202312 6.403 306.746 6.971
202403 9.278 312.332 9.920
202406 7.057 314.175 7.501
202409 4.576 315.301 4.847
202412 2.044 315.605 2.163
202503 -0.586 319.799 -0.612
202506 3.438 322.561 3.559
202509 1.064 324.800 1.094
202512 -0.554 324.054 -0.571
202603 11.103 330.213 11.229
202606 3.001 333.952 3.001

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunic Business Description

Other Exchanges 10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for IMUX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.40
Price